Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective

PURPOSE: The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300 mg) and palonosetron (0.5 mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Jonas, Piovesana, Vittoria, Turini, Marco, Lezzi, Claudio, Eriksson, Jennifer, Aapro, Matti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633536/
https://www.ncbi.nlm.nih.gov/pubmed/36074186
http://dx.doi.org/10.1007/s00520-022-07339-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633536/
https://www.ncbi.nlm.nih.gov/pubmed/36074186
http://dx.doi.org/10.1007/s00520-022-07339-1

Ejemplares similares